Bénedith Oben is Business Analyst at Hyloris Pharmaceuticals, located in Liège, Belgium. After her biomedical science studies at Hasselt University, Bénedith did a PhD where she investigated the genomic profiles and molecular drivers in patients progressing to the hematological malignancy multiple myeloma. At the beginning of 2022, she joined the business development team of the pharmaceutical company Hyloris, specifically committed to bringing innovative, value-added medicines that address the unmet (medical) needs of underserved patient populations through reinventing existing medications.
The development strategy focuses on reformulating and repurposing of approved pharmaceuticals in order to improve overall therapy outcomes for the benefit of patients, physicians, and the healthcare systems.
